Samsung Biologics Co.,Ltd.
207940
🕒 Price Jul 29, 07:34 KST
The overall grade and 100-point score are Premium-only. The 6-metric analysis below is free.
See Premium →Investment caution signals
Automatic signals from DART filings and price trends. “Filing” items are detected from the last 180 days of electronic disclosures. Verify facts against the original filings/news. Not a buy/sell recommendation.
💰 Valuation at a glance
Yahoo FinancePrice ÷ EPS. Lower is cheaper vs earnings. Forward-earnings basis.
Theoretical fair value from PER/PBR and upside (under/overvalued) at a glance. Unlock on Premium.
See Premium →📊 Price trend
Open in Multi-chart →Yahoo Finance📈 Key metrics
Yahoo Finance🏢 Peer comparison
Pharma / BiotechSide by side with the largest names in the same sector. Green beats the sector median.
| Stock | PER | PBR | ROE | Dividend |
|---|---|---|---|---|
| Samsung Biologics Co.,Ltd.Current | 40.2× | 9.62× | 23.9% | — |
| Celltrion, Inc. | 35.5× | 2.12× | 6.0% | 0.4% |
| SK Biopharmaceuticals Co., Ltd. |
🏦 Dividend vs deposit rate
This stock pays no dividend (or has no dividend data), so it isn't directly comparable to a deposit rate. It may be a growth name that relies on price appreciation instead.
As of: Bank of Korea weighted-avg deposit rate · 3.00% (2026-05)
📡 Technical signals
📊 Uptrend alignment (short-term bullish) · RSI 65 neutral
Above the moving averages means short-term bullish; below means bearish. RSI ≥ 70 is overbought and ≤ 30 is oversold.
🎮 What if you had bought?
If you'd bought Samsung Biologics Co.,Ltd. in the past, what would it be worth now? Play with the period and amount. (For reference · not a buy recommendation)
※ Simple close-price math, excluding fees, taxes and dividends. Past returns don’t guarantee future results.
📰 Related news
Source: Naver Finance (KR) · Yahoo Finance (US) · external article links
💼 Financial statements
Yahoo FinanceRecent annual
| Period | Revenue | Op. income | Net income | Op. margin |
|---|---|---|---|---|
| 2025 FY | ₩4.56T | ₩2.07T | ₩1.78T | 45.4% |
| 2024 FY | ₩3.50T | ₩1.32T | ₩1.08T | 37.8% |
| 2023 FY | ₩3.69T | ₩1.11T | ₩857.7B | 30.1% |
| 2022 FY | ₩3.00T | ₩983.6B | ₩798.1B | 32.8% |
Quarterly results (last 5 quarters)
📚 Metrics & scoringShow moreCollapse
🔎 Data sources & methodologyShow moreCollapse
Every score is auto-computed from the public data below. No manual adjustment.
| Item | Source | Method · update cadence |
|---|---|---|
| Price · volume · 52W | Yahoo Finance | Stored as-is · hourly intraday |
| Financials (revenue, profit, equity, debt) | Yahoo fundamentalsTimeSeries | Annual + quarterly reported · refreshed over ~1 week |
| Short-term (TTM) score | Computed (quarterly financials) | Sum of last 4 quarters + YoY momentum vs same quarter a year ago · daily |
| PER · PBR | Computed (KR) | Market cap ÷ latest annual net income / equity · N/A on loss or capital impairment |
| Dividend yield | Yahoo Finance | Annual dividend ÷ price · 0% if none |
| ROE · operating margin · debt ratio |